ESMO 2018 - Results from #80

ESMO 2018: 12-Year Follow-Up of GETUG-12, A Phase 3 Trial of Docetaxel-Based Chemotherapy in High-Risk Localized Prostate Cancer

Munich, Germany (UroToday.com) In this presentation of GU related abstracts for ESMO 2018, Karim Fizazi, MD provides an update on the GETUG-12 study, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer. High-risk prostate cancer has many definitions, but the common theme is that they represent about 15-20% of prostate cancer diagnoses.

ESMO 2018: Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Bone-Predominant mCRPC

Munich, Germany (UroToday.com) Radium-223 is an alpha emitter which selectively treats bone metastases with alpha radiation¹. In a recent GU ASCO oral presentation, a radium-223 pharmacodynamic study demonstrated that higher gamma emission is found in deep tumor containing regions of bone biopsies, compared with superficial regions, supporting the presumed mechanism of radium-223².

ESMO 2018: ERA 223 - A Phase 3 Trial of Ra-223 in Combination with Abiraterone Acetate & Prednisone for the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with mCRPC

Munich, Germany (UroToday.com) As has been the trend in management of advanced solid malignancies, there has been increasing interest in combining proven therapies to identify synergistic effect – survival benefit greater than any one drug alone could provide. This is particularly useful if the mechanism of action of these combined agents targets different pathways.

ESMO 2018: Cabazitaxel vs Abiraterone or Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer Patients

Munich, Germany (UroToday.com) Cabazitaxel, abiraterone, and enzalutamide have demonstrated benefit in randomized controlled trials for patients with mCRPC. Abiraterone was shown to be effective in patients pre and post-chemotherapy in Cougar 301 and Cougar 302^1,2. In patients who had not been treated with docetaxel, abiraterone significantly improved median overall survival compared with placebo (34.7 months vs 30.3 months, HR 0.81 (95% CI 0.70–0.93), p=0·0033). In patients who had progressed on docetaxel, overall survival with abiraterone was 14.8 months, compared with 10.9 months on placebo (HR 0.65, 95% CI 0.54 to 0.77; P<0.001).

ESMO 2018: A Randomized Phase 2 Study of Cabazitaxel vs Abiraterone or Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer

Munich, Germany (UroToday.com) The paradigm of advanced prostate cancer management has drastically changed and continues to do so rapidly. The new focus is on combination therapy to help maximize the synergistic effect by targeting multiple pathways. The current standard of care for metastatic castration-resistant prostate cancer (mCRPC) includes docetaxel (the original standard) and abiraterone/enzalutamide (oral androgen-axis targeted agents that supplanted docetaxel). As abiraterone and enzalutamide are given orally, they are being increasingly utilized in this disease space.

ESMO 2018: Updated Results of GETUG-12, a Phase III Trial Of Docetaxel-Based Chemotherapy In High-Risk Localized Prostate Cancer, with a 12-Year Follow-Up

Munich, Germany (UroToday.com) An estimated 15% of patients are diagnosed with high-risk prostate cancer and 30-50% of these patients will die of their cancer¹. This is an important patient population which may be increasing in the United States given changes to prostate cancer screening by the USPSTF. GETUG-12 was a randomized phase III trial at 26 French hospitals, where patients with high risk localized prostate cancer were randomized to ADT + docetaxel and estramustine or ADT alone².

Huge Variations Between Countries in Time for Reimbursement Decisions on New Cancer Drugs

San Francisco, CA USA (UroToday.com) -- Some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions to reimburse new cancer drugs following their approval by the European Medicines Agency (EMA). The average decision time is longer than one year in some countries, according to a study to be reported at ESMO 2018 Congress ¹.

ESMO Women for Oncology Forum Focuses on Power Sharing to Foster Gender Equality

San Francisco, CA USA (UroToday.com) -- The Women for Oncology (W4O) Forum at ESMO 2018, Sharing the Power, on Friday 19 October¹ will focus on power sharing between women and men working as a way of fostering gender equality in the oncology workforce. Through keynote presentations, testimonies from national networks, and small group discussions, the Forum will explore opportunities for creating a more diverse and inclusive culture that values differences and collaboration.

Financial Impacts of Cancer Found to Intensify Disease Burden Among German Patients

San Francisco, CA USA (UroToday.com) -- A study conducted in Germany draws attention to the fact that the socio-economic burden of cancer is real in Europe too, and not only in the context of the US healthcare system where it has been associated with higher morbidity and mortality. The results to be presented at the ESMO 2018 Congress in Munich show that income loss is the main source of perceived financial hardship and that this is associated with adverse psychological effects in patients.

Trust in Non-conventional Therapies by Cancer Patients Not Matched with Proper Awareness About Their Risks

San Francisco, CA USA ( UroToday.com) -- Sarcoma patients show great openness to the use of complementary alternative medicines (CAMs) for supportive care, but they are poorly informed about safety issues and risk of interactions with anti-cancer drugs, a study to be presented at ESMO 2018 reported. ^¹

Janssen to Showcase Robust Oncology Portfolio at ESMO 2018 Congress

San Francisco, CA USA (UroToday.com) -- The Janssen Pharmaceutical Companies of Johnson & Johnson will present updates from across its oncology portfolio at the European Society for Medical Oncology (ESMO) 2018 annual congress, taking place on 19-23 October in Munich, Germany. Phase 3 data from the SPARTAN study reporting health-related quality of life outcomes in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide will be included in a poster session, with a further poster session highlighting data for ZYTIGA® (abiraterone acetate) in metastatic hormone-sensitive prostate cancer. For erdafitinib in metastatic bladder cancer, a poster session will include an overview of the Phase 3 clinical trial design, and results from a Phase 2a study in advanced cholangiocarcinoma will be featured in a poster discussion.

Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress

San Francisco, CA USA (UroToday.com) -- Exelixis, Inc. announced that data from clinical trials of cabozantinib will be the subject of 13 presentations at the European Society for Medical Oncology (ESMO) 2018 Congress, which is being held October 19-23, 2018 in Munich, Germany.

Bayer to Showcase Latest Oncology Research at ESMO 2018 Congress

San Francisco, CA USA (UroToday.com) -- Bayer will present new data from the company's growing oncology portfolio at the ESMO 2018 Congress (European Society for Medical Oncology) taking place October 19-23 in Munich, Germany. Among the research presented will be an expanded pivotal trial data set on larotrectinib, a TRK (tropomyosin receptor kinase) inhibitor in development for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

Merck’s Broad Oncology Pipeline to Be Highlighted at ESMO 2018 Congress

San Francisco, CA USA (UroToday.com) -- Merck, known as MSD outside the United States and Canada, announced that new data from Merck’s broad oncology portfolio and robust early pipeline will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany from October 19-23. More than 100 abstracts involving Merck medicines – including eight late-breaking abstracts – across more than 15 tumor types have been accepted.

Targeted Drugs for Advanced Cancer Move From Specialist Units to Community Setting

San Francisco, CA USA (UroToday.com) -- Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours. This achievement, to be reported at the ESMO 2018 Congress in Munich,¹shows that cutting-edge precision medicine is spreading from highly specialist cancer units to other healthcare facilities so more patients can benefit, wherever they are treated.

Clovis Oncology to Highlight Results from Rucaparib TRITON Prostate Program at ESMO 2018 Congress

San Francisco, CA USA (UroToday.com) -- Clovis Oncology, Inc. announced that four posters featuring data and highlighting studies from the Rubraca® clinical development program will be presented at the ESMO 2018 Congress (European Society for Medical Oncology), 19-23 October, 2018, in Munich, Germany. These posters include the first presentation of initial results from the Phase 2 TRITON2 clinical trial of Rubraca, an oral, small molecule PARP inhibitor, in advanced mCRPC, as well as genomic profiling data based on tumor tissue and plasma cfDNA samples from patients who were screened following progression on prior therapy for enrollment in TRITON2 or the Phase 3 TRITON3 clinical study.

Page 5 of 5